<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219762</url>
  </required_header>
  <id_info>
    <org_study_id>GOIRC-02-2016</org_study_id>
    <nct_id>NCT03219762</nct_id>
  </id_info>
  <brief_title>Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC</brief_title>
  <acronym>Nabster</acronym>
  <official_title>Phase II Study of Nab-paclitaxel in Sensitive and Refractory Relapsed Small Cell Lung Cancer (Nabster Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Temas srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clirest s.r.l.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mipharm S.p.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Toscano Tumori - Centro per il Coordinamento delle Sperimentazioni Cliniche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Oncologico Italiano di Ricerca Clinica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the activity and safety of Nab-paclitaxel in patients with sensitive or refractory
      SCLC who relapsed after cisplatin or carboplatin and etoposide first-line chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, multicentre, study</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point is objective tumor response</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 weeks.</time_frame>
    <description>It will be evaluated according to standard RECIST 1.1 criteria and will be based on the Investigator's assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Toxicity Events: frequency of moderate and severe toxicity events and drop-out rate due to therapy related toxicity</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 weeks.</time_frame>
    <description>The assessment of safety will be based mainly on the frequency of adverse events. Adverse events will be summarized by presenting the number and percentage of patients having any adverse event, having an adverse event in each body system and having each individual adverse event.
Toxicity descriptive tables will be produced which provide the worst degree of toxicity measured over all cycles according to the CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of registration until the date of last documented progression or date of death from any cause, assessed up to 100 weeks</time_frame>
    <description>will be calculated from the patient registration to the evidence of progressive disease, or death, or the last date the patient was known to be progression-free or alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of patient enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>will be calculated from the registration to death from any cause, or the last date the patient was known to be alive from the registration to death from any cause, or the last date the patient was known to be alive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabpaclitaxel</intervention_name>
    <description>Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study</description>
    <arm_group_label>Nab-paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically (histology or cytology) confirmed diagnosis of small cell lung cancer
             (SCLC) or large-cell neuroendocrine carcinoma (LCNEC) or poorly differentiated (G3)
             neuroendocrine cancer of the lung (according to WHO classification 2015)

          -  Male or female and ≥ 18 years of age

          -  Life expectancy ≥ 12 weeks

          -  Have progressed after or during platinum-based standard chemotherapy regimen
             (cisplatin or carboplatin and etoposide) for first-line treatment of SCLC, either
             limited stage (LD) or extensive stage (ED) disease and have not received any other
             treatment (except for immunotherapy as maintenance treatment), including re-treatment
             with front-line regimen

          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1
             (RECIST 1.1); clear radiological evidence of disease progression after first-line
             therapy has to be documented; no previous radiotherapy on the only site of measurable
             or evaluable disease, unless that site had subsequent evidence of progression

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Patients with treated brain metastases with stable lesions for at least 2 weeks and
             off steroids or on a stable dose of steroids. Radiotherapy must have been completed a
             minimum of 14 days prior to registration, and patients must have recovered from AEs
             related to radiotherapy to &lt; grade 1 (except alopecia)

          -  For Females: must be postmenopausal (defined as occurring 12 months after last
             menstrual period) before the screening visit, or are surgically sterile. If they are
             of childbearing potential, a negative serum pregnancy test prior to study entry has to
             be documented; furthermore, they agree to practice 2 effective methods of
             contraception, at the same time, from the time of signing the informed consent form
             (ICF) through 30 days after the last dose of study drug, or agree to practice true
             abstinence, when this is in line with the preferred and usual lifestyle of the subject

          -  For Males: even if surgically sterilized (i.e. post-vasectomy status) agree to
             practice effective barrier contraception during the entire study treatment period and
             through 6 months after the last dose of study drug, or practice true abstinence, when
             this is in line with the preferred and usual lifestyle of the subject

          -  Screening clinical laboratory values as specified below:

               -  Absolute neutrophil count (ANC) ≥ 1500/mm3, platelet count ≥ 100,000/mm3 and
                  haemoglobin ≥ 9 g/dL

               -  Total bilirubin &lt; 1.5 the institutional upper limit of normal (ULN)

               -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 2.5
                  the institutional ULN (&lt; 5 if liver function test elevations are due to liver
                  metastases)

               -  Creatinine &lt; 1.5 institutional ULN or estimated creatinine clearance using the
                  Cockcroft-Gault formula ≥ 30 mL/minute for patients with creatinine levels above
                  institutional limits

          -  Stable medical condition, including the absence of acute exacerbations of chronic
             illnesses, serious infections, or major surgery within 4 weeks before registration,
             and otherwise noted in other inclusion/exclusion criteria

          -  Recovered (i.e., ≤ Grade 1 toxicity) from effects of prior anticancer therapy, except
             alopecia

          -  Prior radiotherapy is allowed provided that it has been completed more than 2 weeks
             before starting Nab-paclitaxel

          -  Ability to comply with protocol requirements

          -  The patient or the patient's legal representative has to be able to provide written
             informed consent. Voluntary written consent must be given before performance of any
             study-related procedure not part of standard medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to future
             medical care

        Exclusion Criteria:

          -  Any prior not platinum-based chemotherapy treatment for SCLC or large-cell
             neuroendocrine carcinoma (LCNEC) or poorly differentiated (G3) neuroendocrine cancer
             of the lung (according WHO classification 2015) (immunotherapy is allowed as
             maintenance treatment)

          -  Prior treatment with Nab-paclitaxel, paclitaxel or any other taxane agent

          -  Known hypersensitivity to Cremophor EL®, paclitaxel, or its components

          -  Any comorbid condition or unresolved toxicity that would preclude administration of
             weekly Nab-paclitaxel

          -  Prior history of Grade ≥ 2 neurotoxicity that is not resolved to ≤ Grade 1

          -  Patients with symptomatic and/or progressive brain metastases or with carcinomatous
             meningitis

          -  Diagnosed with or treated for another malignancy within 3 years before the first dose
             of study drug, or previously diagnosed with another malignancy and have any evidence
             of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of
             any type may be enrolled in the study if they have undergone complete resection and no
             evidence of active disease is present

          -  History of myocardial infarction, unstable symptomatic ischemic heart disease,
             uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac
             arrhythmias of Grade &gt; 2, thromboembolic events (e.g., deep vein thrombosis, pulmonary
             embolism, or symptomatic cerebrovascular events), or any other cardiac condition (egg,
             pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving
             the first dose of study drug. Chronic stable atrial fibrillation on stable
             anticoagulant therapy is allowed. Patients with a pacemaker may be enrolled in the
             study upon discussion with the project clinician

          -  Infection requiring IV antibiotic therapy or other serious infection within 14 days
             before the first dose of study drug

          -  For female subjects: positive serum pregnancy test, pregnancy or breast feeding

          -  Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrolment and not
             fully recovered to baseline or to a stable clinical status. Insertion of a vascular
             device is allowed

          -  Unwilling or unable to comply with the protocol or cooperate fully with the
             investigator and site personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GOIRC</last_name>
    <phone>00390512142204</phone>
    <email>nabsterstudy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Ardizzoni, PI</last_name>
    <phone>00390512142204</phone>
    <email>andrea.adizzoni@aosp.bo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UO di Oncologia Ematologia, Azienda Ospedaliero Universitaria di Ferrara</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Frassoldati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione Pneumo-Oncologica - Medicina Interna I; IRCCS &quot;Casa Sollievo della Sofferenza&quot;</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vito D'Alessandro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, IRST. Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori, IRCCS di Meldola</name>
      <address>
        <city>Meldola</city>
        <state>Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angelo Del Monte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica - Ospedale Versilia</name>
      <address>
        <city>Lido di Camaiore</city>
        <state>Lucca</state>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrea Camerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC di Oncologia Medica, A.O. San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Diego Cortinovis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Medicina Oncologica Ospedale di Carpi (MO)</name>
      <address>
        <city>Carpi</city>
        <state>Modena</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucia Longo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica - Ospedale di Saronno</name>
      <address>
        <city>Saronno</city>
        <state>Varese</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claudio Verusio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica, Azienda ULSS21 di Legnago</name>
      <address>
        <city>Legnago</city>
        <state>Verona</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Ospedale Sacro Cuore - Don Calabria - Negrar (VR)</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stefania Gori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Oncologia - ASO &quot;SS Antonio e Biagio e Cesare Arrigo,Alessandria</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Perluigi Piovano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniche Humanitas Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Luca Ceresoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Ospedale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Bettini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO di Oncologia Medica, Azienda Ospedaliero-Universitaria S. Orsola Malpighi di Bologna,</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Ardizzoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica - Ospedale di Bolzano,</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emanuela Vattemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica PO A.Perino ASL di Brindisi</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Saverio Cinieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC di Oncologia, Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Matteo Brighenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica A.O. Santa Croce e Carle Ospedale Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ida Colantonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Careggi, UO di Oncologia Medica</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Di Costanzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia, Azienda USL di Imola, Ospedale Santa Maria della Scaletta</name>
      <address>
        <city>Imola</city>
        <zip>40028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Maestri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico, Azienda USL 2 di Lucca, Ospedale San Luca</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carmelo Tibaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena-Policlinico, U.O. di Oncologia Medica ed Ematologia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fausto Barbieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. C. di Oncologia Medica AORN &quot;Antonio Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ferdinando Riccardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica di Parma, Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcello Tiseo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia e Ematologia, UO di Oncologia Medica Azienda USL di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Ematologia. UO di Oncologia Medica, AUSL della Romagna, Ospedale Santa Maria delle Croci di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Dazzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera Molinette, U.O. di Oncologia Medica</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Libero Ciuffreda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

